Relapsed Acute Lymphoblastic Leukemia (ALL) Terminated Phase 1 Trials for Cytarabine (DB00987)

Back to Relapsed Acute Lymphoblastic Leukemia (ALL)

Also known as: Acute Lymphoblastic Leukemia, in Relapse / Relapsed ALL / Relapsed Acute Lymphoblastic Leukemia / Acute, relapsed Lymphoblastic Leukemia

Indication	Status	Phase
DBCOND0069491 (Relapsed Acute Lymphoblastic Leukemia (ALL))	Terminated	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03515200	Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia	Treatment	Bortezomib (DB00188) Cytarabine (DB00987) Dasatinib (DB01254) Dexamethasone (DB01234) Doxorubicin (DB00997) Hydrocortisone (DB00741) Methotrexate (DB00563) Palbociclib (DB09073) Ruxolitinib (DB08877)
NCT00928200	Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)	Treatment	Asparaginase Erwinia chrysanthemi (DB08886) Asparaginase Escherichia coli (DB00023) Cytarabine (DB00987) Dexamethasone (DB01234) Dexrazoxane (DB00380) Doxorubicin (DB00997) Methotrexate (DB00563) Vincristine (DB00541)